Worldwide, stroke is the second leading cause of death1 and occurs when blood supply to the brain is interrupted or reduced, preventing brain tissue from getting oxygen.
At Biogen, we aspire to improve the lives of those suffering from strokes and secondary injuries by developing therapies and solutions to address the areas of greatest unmet need.
By tapping into our connections in the stroke medical community, harnessing our scientific expertise in neurological disorders, and channeling the strength of our pipeline, we’re working to create innovative therapies and digital health solutions that have the potential to transform the standard of care in stroke.
Kim Richard-O'Brien, Vice President, Global Head of Scientific Partnerships – Worldwide Medical at Biogen, recalls her experiences with stroke and underscores why immediate action is critical to optimizing patient outcomes.
Biogen conducts clinical trials in stroke related to the investigational therapies in our pipeline to evaluate the efficacy and safety of potential medicines.
View all recruiting Biogen clinical trials in stroke
Deciding to participate in a clinical trial requires careful consideration. In most cases, the therapies investigated in clinical trials are not yet approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). The benefits and risks of taking the treatment are not completely known. By volunteering for a clinical trial, you are helping the medical community determine whether new treatments are safe and effective.
Learn more about clinical trials and access programs
At least 13 million people suffer a stroke each year, and more than 5 million ultimately die as a result.1
Every 40 seconds, a person suffers a stroke.2
Stroke risk increases with age, but more than a third of all stroke victims are less than 65 years old3.